Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just after your understanding of the latest time table for SCIB2. It says toxicology study to start in Q4 2018 and be completed in H1 next year. Just to confirm is this the phase1/2 trial or is this just the pre clinical work? Many thanks
Correct, this latest funding round is to begin the SCIB1 combo trial and MOD1 trial. I see they say on the OO document that the first part of the SCIB1 Combo trial will be finished in H1 next year and then the second part in H2 of 2020. From the latest presentation on the Scancell website is says there will be 25 patients total in the Combo trial, 6 in part 1 and 19 in part 2. I�m wondering if when Part 1 is complete they seek the funds then if results are as expected or possibly and hopefully seek a partner.
Frustrating all round to a degree, the share price appeared on the face of it to be making some headway of late, but we all know the possibility of what was needed should no deal arrive. At least now we can get a trial started and move things along somewhat. Still looking for some BioNtech action in the next 12 months.
Is it really left field when we already know about it? BioNtech and scancell enter into an initial research collaboration with possible licensing option for follow was the initial RNS about this. In the last scancell presentation I think it said the TCR stuff should be finished H1 next year but CH in today’s video said maybe end of this year. It’s definitely the best bet / only bet that we know of at the moment that could yield something similar to what we all would like!
Would be surprised to see one until the EFW is completely finished and put to bed with debt coming down.
I believe they will get an agreement sorted with the lenders and in due course will begin to recover. �60 million operating profit pencilled in for this year so eps of around 35p of course unless current trading worsens further. The new management will come up with a plan going forward but it will be a bumpy road. A few positives, at least some aspects of the business still performing well / improving and also the order book is higher than at the Half yearly.
Agreed. The bank covenants are the issue. They could just pull the plug but I doubt they will as they have a vested interest in seeing that debt repaid (which of course they could demand sale of the assets) but I think they come up with a renogotiated agreement. But at least now we have a management that are looking at ways to improve things. Equipment services still performing well and improving. The increased outflow was pretty much as numis and Liberum expected in September £160 - £190 million. Now we have £195 million. ‘Uncertainty remains’. That is still a risk.
About as good as could be expected. Operating profit for full year to come in at £90 mil approx Bank covenants an issue. I bank on them coming up with a new agreement
Forecast reduced again slightly
Decent close considering the drop earlier. Hopefully can make some head way tomorrow
Went from overweight to equal weight....Target price £16.00 Probably cussed the drop. Annoying as it had gained a bit of traction yesterday
Looking for a move up prior to the report. Any 'bad news' out there now?
I'm looking for a move into net cash and the continued growth shown previously. Hopefully the market can respond too.
Is it weekend press?
$175 million (dollars) Is the projected EBITDA of the combined group. So approx £110mil. Still cheap!